Home › Research › Treatments
[Pathophysiology and Clinical Presentation of Amyloid-Related Imaging Abnormality Induced by Anti-Amyloid-β Antibody Lecanemab]
Tomimoto H, Matsumoto M, Shiina H, Saeki Y, Niidome T, Nakamura Y.. Brain and nerve = Shinkei kenkyu no shinpo, 2025-02-01
Topic: Amyloid, tau and blood-test diagnosis
Lecanemab, the first monoclonal antibody drug targeting amyloid beta (Aβ), was approved for slowing the progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in the United States and Japan. On the other hand, Amyloid-related imaging abnormalities (ARIA) has been reported in clinical trials, and its management and countermeasures remain a clinical issue. Given the large number of patients who is indicated of and would benefit from this type of AD therapy, physicians prescribing lecanemab should be familiar with how to appropriately manage and reduce the risks of ARIA. In this review, we outline the imaging characteristics and pathogenesis of ARIA that have emerged from the clinical trials and will also discuss risk factors and management protocol. (Recieved April 12, 2024; Accepted September 18, 2024; Published February 1, 2025).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Tomimoto, H., Matsumoto, M., Shiina, H., Saeki, Y., Niidome, T., & Nakamura, Y. (2025). [Pathophysiology and Clinical Presentation of Amyloid-Related Imaging Abnormality Induced by Anti-Amyloid-β Antibody Lecanemab]. Brain and nerve = Shinkei kenkyu no shinpo. https://doi.org/10.11477/mf.188160960770020175
Vancouver
Tomimoto H, Matsumoto M, Shiina H, Saeki Y, Niidome T, Nakamura Y. [Pathophysiology and Clinical Presentation of Amyloid-Related Imaging Abnormality Induced by Anti-Amyloid-β Antibody Lecanemab]. Brain and nerve = Shinkei kenkyu no shinpo. 2025. doi:10.11477/mf.188160960770020175. PMID: 39935267.
BibTeX
@article{tomimoto2025-39935267,
author = {Tomimoto, H. and Matsumoto, M. and Shiina, H. and Saeki, Y. and Niidome, T. and Nakamura, Y.},
title = {{[Pathophysiology and Clinical Presentation of Amyloid-Related Imaging Abnormality Induced by Anti-Amyloid-β Antibody Lecanemab]}},
journal = {Brain and nerve = Shinkei kenkyu no shinpo},
year = {2025},
doi = {10.11477/mf.188160960770020175},
pmid = {39935267},
url = {https://doi.org/10.11477/mf.188160960770020175}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Lecanemab, the first monoclonal antibody drug targeting amyloid beta (Aβ), was approved for slowing the progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in the United States and Japan.
- On the other hand, Amyloid-related imaging abnormalities (ARIA) has been reported in clinical trials, and its management and countermeasures remain a clinical issue.
- Given the large number of patients who is indicated of and would benefit from this type of AD therapy, physicians prescribing lecanemab should be familiar with how to appropriately manage and reduce the risks of ARIA.
- In this review, we outline the imaging characteristics and pathogenesis of ARIA that have emerged from the clinical trials and will also discuss risk factors and management protocol.
- (Recieved April 12, 2024; Accepted September 18, 2024; Published February 1, 2025).
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 24 of the 58 points we could judge it on, which is 41 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Brain and nerve = Shinkei kenkyu no shinpo) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39935267) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 24 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 24 of the 58 points we could judge it on is 41 out of 100. |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments
Also tagged “clinical-presentation”
3 studies in the library carry the topic tag “clinical-presentation”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 3 tagged studies.